Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparing gene expression profiles of pigmented and amelanotic (MPNST-like) melanomas arising in the genetically engineered BRAF(V600E)-Cdk4(R24C) mouse melanoma model

ABSTRACT: We found that pigmented and amelanotic (MPNST-like) melanomas arise in the genetically engineered BRAF(V600E)-Cdk4(R24C) mouse melanoma model and even in the same animal. To explore the molecular differences between the two type of melanomas in this model we performed global gene expression profiling and pathway analysis to compare the underlying mechanisms. This information was used to identify human melanomas that resemble each type of the mouse melanomas found in the in the genetically engineered BRAF(V600E)-Cdk4(R24C) mouse melanoma model.

ORGANISM(S): Mus musculus

PROVIDER: GSE71879 | GEO | 2015/12/01

SECONDARY ACCESSION(S): PRJNA292395

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mus musculus

Project description:Comparing gene expression profiles of pigmented and amelanotic (MPNST-like) melanomas arising in the genetically engineered BRAF(V600E)-Cdk4(R24C) mouse melanoma model

| PRJNA292395 | ENA

Endogenous RAC1 P29S in mouse melanoma

Project description:We studied the effects of endogenous expression of the melanoma oncogene RAC1 P29S in BRAF V600E;PTEN hemizygous mouse melanomas.

2018-08-10 | GSE118344 | GEO

Proteomic analysis of pigmented and amelanotic melanoma cells

Project description:Mass spectrometry-based proteomics comparison between amelanotic and pigmented melanoma cells for new biomarkers discovery.

2023-02-14 | PXD033192 | Pride

Gene expression profile analysis of inducible melanotic and amelanotic melanoma in mice

Project description:We analyzed an inducible melanoma model in TiRP Ink4a/ArfF/F B10.D2 mice based on the conditional deletion in melanocytes of two tumor suppressor genes INK4a/Arf coupled to the expression of the oncogene H-rasG12V and a known tumor antigen (Hujibers et al. Cancer Res. 66:3278,2006; Soudja et al. Cancer Res. 70:3515-3525,2010). About 40% of these mice develop melanomas. Some tumors are heavily pigmented melanotic melanoma and grow slowly (hereafter referred to as “Mela”), but most of the induced tumors are nonpigmented amelanotic melanomas which are more aggressive (hereafter referred to as “Amela”). Gene expression profiles of the two types of tumors and of Amela-derived cell lines established in vitro were analyzed to identify the transcriptional signatures of these two types of tumors (including stromal components and infiltrating cells), as well as that intrinsic to Amela-tumor cells. 4 Amela and 4 Mela ex-vivo tumors were compared in a dye-swap experiment (8 chips). 4 Amela and 4 Mela ex-vivo tumors were compared to healthy skin (CTRL) (8 chips). 4 Amela ex-vivo tumors and Amela cell lines were compared in a dye-swap experiment (8 chips).

2013-06-26 | E-GEOD-29304 | biostudies-arrayexpress

Gene expression profile analysis of inducible melanotic and amelanotic melanoma in mice

2013-06-26 | GSE29304 | GEO

RNA Seq data: A375, A375R, A375DR vorinostat treated, and biopy samples from patients pre- and post- treated with Vorinostat

Project description:BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance, which is frequently caused by reactivation of the Mitogen Activated Protein Kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with increased levels of reactive oxygen species (ROS). Subsequent treatment with the histone deacetylase inhibitor (HDACi) vorinostat represses SLC7A11 that leads to a lethal increase in the already elevated levels of ROS in drug-resistant cells, thereby causing selective apoptotic death of only the drug resistant tumor cells. Consistently, treatment of BRAF inhibitor-resistant melanoma with HDACi in mice results in a dramatic tumor regression. In a study in patients with advanced BRAF+MEK inhibitor resistant melanoma, we find that HDACi can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.

2018-04-18 | GSE110948 | GEO

Expression data from second oncogene expressing Melanoma Cells.

Project description:Among the myriad tumors analyzed to date, cutaneous malignant melanomas bear some of the highest mutational burdens. Thus, it is somewhat surprising that oncogene exclusion between is so pronounced in melanomas where there is only a single melanoma out of 366 sequenced specimens which harbors concurrent BRAF(V600E/M) and NRAS(G13R) mutations (TCGA-ES-A2NC Sample; WWW.bioportal.org), In this senario some NRAS and BRAF mutations co-expressing cells show slow growth phenotypes by under study mechanism. We used Affymetrix GeneChip Expression Arrays to detail the global programme of gene expression underlying oncogenic exclusion and identified distinct classes of up and down-regulated genes during this process.

2018-11-22 | GSE122835 | GEO

Distinct gene expression patterns of highly and poorly malignant melanocytic tumors from genetically engineered mouse models of mice carrying specific inactivating mutations in Ink4A or ARF respectively

Project description:Cutaneous malignant melanoma is among the most deadly human cancers, broadly resistant to most clinical therapies. A majority of patients with BRAFV600E melanomas respond well to inhibitors such as vemurafenib, but all ultimately relapse. Moreover, there are no viable treatment options available for other non-BRAF melanoma subtypes in the clinic. A key to improving treatment options lies in a better understanding of mechanisms underlying melanoma progression, which are complex and heterogeneous. In this study we perform gene expression profilling of highly and poorly malignant melanocytic tumors from genetically engineered mouse models to discover important drivers of cancer progression.

2017-02-01 | GSE87331 | GEO

Tumor genetic heterogeneity analysis of chronic sun-damaged melanomas

Project description:Chronic sun-damaged (CSDhigh) melanoma represents 10-20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load. However, the order of genetic events, or the extent of intra-tumor heterogeneity (ITH) in CSDhigh melanoma is still unknown. Ultra-deep targeted sequencing of 40 cancer-associated genes was performed in 73 in situ or invasive CMM, including 23 CSDhigh cases. In addition, we performed whole-exome and RNA sequencing on multiple regions of primary tumor and multiple in-transit metastases from one CSDhigh melanoma patient. We found no significant difference in mutation frequency in melanoma-related genes or in mutational load between in situ and invasive CSDhigh lesions while this difference was observed in CSDlow lesions. In addition, increased frequency of BRAF V600K, NF1 and TP53 mutations (P < 0.01, Fisher’s Exact Test) was found in CSDhigh melanomas. Sequencing of multiple specimens from one CSDhigh patient revealed strikingly limited ITH with > 95% shared mutations. Our results provide evidence that CSDhigh and CSDlow melanomas are distinct molecular entities that progress via different genetic routes.

2020-05-19 | GSE139362 | GEO

DNA Seq data: biopy samples from patients pre- and post- treated with Vorinostat

2018-04-18 | GSE111140 | GEO